GenTraceDx for Patients
GenTraceDx is a precision oncology platform designed to help you and your healthcare team better understand your cancer through comprehensive genomic analysis and continuously updating clinical interpretation.
Physicians and clinical sites are currently invited to pre-enrol and will be notified as the pilot progresses and patient enrolment becomes available. If you are interested in participating, we encourage you to discuss the study with your oncologist.
Why This Matters for You
Cancer research is advancing rapidly. New biomarkers, targeted therapies, clinical trials, and scientific discoveries continue to expand the treatment options available for many patients.
Most precision oncology tests provide a single interpretation based on the knowledge available at the time of testing. As new evidence emerges, additional clinically relevant findings and therapeutic opportunities may become available.
GenTraceDx was designed to help your healthcare team continually re-evaluate your cancer as scientific knowledge evolves.
GenTraceDx is different
GenTraceDx is designed to:
- Perform comprehensive tumour-normal DNA and RNA analysis
- Identify clinically relevant biomarkers and potential therapeutic opportunities
- Continuously re-evaluate your molecular profile as new scientific evidence emerges
- Provide your healthcare team with continuously updated clinical interpretation throughout your cancer journey
How GenTraceDx Works
Step 1
Speak with your oncologist
Download GenTraceDx national pilot information sheet (PDF) and discuss whether the study may be appropriate for you. If your oncologist is interested, they can pre-enrol to receive pilot updates and participation information.
Step 2
Comprehensive molecular analysis is performed
Your tumour and normal samples undergo comprehensive genomic and transcriptomic (RNA) analysis to better understand the unique molecular characteristics of your cancer.
Step 3
Your oncologist receives your initial report
Your healthcare team receives a comprehensive precision oncology report summarizing clinically relevant findings and potential therapeutic opportunities.
Step 4
Your results continue to evolve
As new scientific evidence emerges, GenTraceDx continuously re-evaluates your molecular profile to identify additional clinically relevant findings and potential therapeutic opportunities.
Step 5
Stay informed throughout your care
You and your healthcare team can securely access updated reports and clinical insights as new evidence becomes available.
GenTraceDx National Pilot (Canada)
Goals of the Pilot:
- Evaluate the clinical utility of comprehensive genomic and transcriptomic analysis
- Assess the value of continuously updating clinical interpretation
- Help identify clinically relevant therapeutic opportunities and clinical trials
How to Participate
Physicians and clinical sites are currently invited to pre-enrol and will be notified when patient enrolment begins.
• Speak with your oncologist to determine whether the GenTraceDx National Pilot may be appropriate for you.
• If your oncologist has not yet pre-enrolled, download the physician information sheet and encourage them to learn more about the pilot.
• Once patient enrolment begins, participating physicians will be able to determine whether you meet the study eligibility criteria.
Share with Your Care Team
- Overview of the GenTraceDx platform
- National pilot overview
- Patient eligibility criteria
- Physician pre-enrolment information
Designed for Ongoing Care
- View their precision oncology reports
- Receive updated clinical insights over time
- Access educational resources
- Stay informed as new scientific evidence emerges
What to Expect
- GenTraceDx is designed to support your healthcare team by providing additional clinically relevant insights.
- It is intended to complement—not replace—the expertise of your treating oncologist.
- It does not guarantee specific treatments or outcomes.
- Treatment recommendations will always be made by your healthcare team based on your individual clinical situation.
All treatment decisions remain the responsibility of your treating oncologist.